Back

11 April 2025

BSG Gut Highlights April 2025

BSG-Gut-Highlights.png

Hepatology:

Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989

Mak L, Wooddell C, Lenz O, et al. Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989. Gut 2025; 74: 440-450. doi: 10.1136/gutjnl-2024-333026.

Read It Here.


Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma

Salié H, Wischer L, D’Alessio A, et al. Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma. Gut 2025; 74: 451-466. doi: 10.1136/gutjnl-2024-332837.

Read It Here.

Endoscopy:

Endoscopic papillectomy versus surgical ampullectomy for adenomas and early cancers of the papilla: a retrospective Pancreas2000/European Pancreatic Club analysis

Hollenbach M, Heise C, Abou-Ali E, et al. Endoscopic papillectomy versus surgical ampullectomy for adenomas and early cancers of the papilla: a retrospective Pancreas2000/European Pancreatic Club analysis. Gut 2025; 74(3):397-409. doi: 10.1136/gutjnl-2022-327996.

Read It Here.

Stomach:

CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases

Li Y, Zheng Y, Huang J, et al. CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases. Gut 2025; 74(3):350-363. doi: 10.1136/gutjnl-2024-333617.

Read It Here.

IBD:

Withdrawal of antitumour necrosis factor in inflammatory bowel disease (IBD) patients in remission: a randomised placebo-controlled clinical trial of GETECCU

Gisbert J, Donday M, Riestra S, et al. Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU. Gut 2025; 74(3): 387-396. doi: 10.1136/gutjnl-2024-333385.

Read It Here.

Reviewers

Dr Catherine Hsu, Gastroenterology Registrar, St Mary’s Hospital, Imperial College Healthcare NHS Trust, London, UK

Dr Kelly Chatten, Bolton NHS Foundation Trust, Bolton, UK

Dr Khurum Hakeem, Gastroenterology Registrar, University Hospital of North Durham, Durham, UK

Dr Abisoye Akintimehin, Gastroenterology Registrar London North West University Healthcare NHS Trust, London, UK

Dr James Sun, Pre-doctoral Clinical Research Excellence Fellow, Francis Crick Institute and King’s College London, London, UK

BSG GUT Highlights is edited by Dr Philip J Smith, Honorary Consultant Luminal Gastroenterologist, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Mount Vernon, Liverpool, UK. Dr Smith is the Digital and Education Editor of GUT, Editor in chief of Frontline Gastroenterology and Associate Editor of BMJ Open Gastroenterology.

Funding

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests: None declared.

Provenance and peer review: Not commissioned; internally peer reviewed.